Iram Ahmad1, Leila R Zelnick2,3, Zona Batacchi2,4, Nicole Robinson2, Ashveena Dighe2,3, Jo-Anne E Manski-Nankervis5, John Furler5, David N O'Neal6, Randie Little7, Dace Trence4, Irl B Hirsch4, Nisha Bansal2,3, Ian H de Boer2,3,8. 1. Division of Endocrinology, Banner-MD Anderson Cancer Center, Gilbert, Arizona; Iram.Ahmad@bannerhealth.com. 2. Kidney Research Institute. 3. Division of Nephrology, and. 4. Division of Metabolism, Endocrinology, and Nutrition, University of Washington, Seattle, Washington. 5. Department of General Practice, University of Melbourne, Carlton, Victoria, Australia. 6. Department of Medicine, St Vincent's Hospital Melbourne, University of Melbourne, Fitzroy, Victoria, Australia. 7. Department of Pathology and Anatomical Sciences, University of Missouri, Columbia, Missouri; and. 8. Puget Sound Veterans Affairs Health Care System, Seattle, Washington.
Abstract
BACKGROUND AND OBJECTIVES: Among people with diabetes mellitus, CKD may promote hypoglycemia through altered clearance of glucose-lowering medications, decreased kidney gluconeogenesis, and blunted counter-regulatory response. We conducted a prospective observational study of hypoglycemia among 105 individuals with type 2 diabetes treated with insulin or a sulfonylurea using continuous glucose monitors. DESIGN, SETTING, PARTICIPANTS & MEASUREMENTS: We enrolled 81 participants with CKD, defined as eGFR<60 ml/min per 1.73 m2, and 24 control participants with eGFR≥60 ml/min per 1.73 m2 frequency-matched on age, duration of diabetes, hemoglobin A1c, and glucose-lowering medications. Each participant wore a continuous glucose monitor for two 6-day periods. We examined rates of sustained level 1 hypoglycemia (<70 mg/dl) and level 2 hypoglycemia (<54 mg/dl) among participants with CKD. We then tested differences compared with control participants as well as a second control population (n=73) using Poisson and linear regression, adjusting for age, sex, and race. RESULTS: Over 890 total days of continuous glucose monitoring, participants with CKD were observed to have 255 episodes of level 1 hypoglycemia, of which 68 episodes reached level 2 hypoglycemia. Median rate of hypoglycemic episodes was 5.3 (interquartile range, 0.0-11.7) per 30 days and mean time spent in hypoglycemia was 28 (SD 37) minutes per day. Hemoglobin A1c and the glucose management indicator were the main clinical correlates of time in hypoglycemia (adjusted differences 6 [95% confidence interval, 2 to 10] and 13 [95% confidence interval, 7 to 20] fewer minutes per day per 1% higher hemoglobin A1c or glucose management indicator, respectively). Compared with control populations, participants with CKD were not observed to have significant differences in time in hypoglycemia (adjusted differences 4 [95% confidence interval, -12 to 20] and -12 [95% confidence interval, -29 to 5] minutes per day). CONCLUSIONS: Among people with type 2 diabetes and moderate to severe CKD, hypoglycemia was common, particularly with tighter glycemic control, but not significantly different from groups with similar clinical characteristics and preserved eGFR.
BACKGROUND AND OBJECTIVES: Among people with diabetes mellitus, CKD may promote hypoglycemia through altered clearance of glucose-lowering medications, decreased kidney gluconeogenesis, and blunted counter-regulatory response. We conducted a prospective observational study of hypoglycemia among 105 individuals with type 2 diabetes treated with insulin or a sulfonylurea using continuous glucose monitors. DESIGN, SETTING, PARTICIPANTS & MEASUREMENTS: We enrolled 81 participants with CKD, defined as eGFR<60 ml/min per 1.73 m2, and 24 control participants with eGFR≥60 ml/min per 1.73 m2 frequency-matched on age, duration of diabetes, hemoglobin A1c, and glucose-lowering medications. Each participant wore a continuous glucose monitor for two 6-day periods. We examined rates of sustained level 1 hypoglycemia (<70 mg/dl) and level 2 hypoglycemia (<54 mg/dl) among participants with CKD. We then tested differences compared with control participants as well as a second control population (n=73) using Poisson and linear regression, adjusting for age, sex, and race. RESULTS: Over 890 total days of continuous glucose monitoring, participants with CKD were observed to have 255 episodes of level 1 hypoglycemia, of which 68 episodes reached level 2 hypoglycemia. Median rate of hypoglycemic episodes was 5.3 (interquartile range, 0.0-11.7) per 30 days and mean time spent in hypoglycemia was 28 (SD 37) minutes per day. Hemoglobin A1c and the glucose management indicator were the main clinical correlates of time in hypoglycemia (adjusted differences 6 [95% confidence interval, 2 to 10] and 13 [95% confidence interval, 7 to 20] fewer minutes per day per 1% higher hemoglobin A1c or glucose management indicator, respectively). Compared with control populations, participants with CKD were not observed to have significant differences in time in hypoglycemia (adjusted differences 4 [95% confidence interval, -12 to 20] and -12 [95% confidence interval, -29 to 5] minutes per day). CONCLUSIONS: Among people with type 2 diabetes and moderate to severe CKD, hypoglycemia was common, particularly with tighter glycemic control, but not significantly different from groups with similar clinical characteristics and preserved eGFR.
Authors: Jennifer Marshall; Peter Jennings; Adrian Scott; Richard J Fluck; Christopher W McIntyre Journal: Kidney Int Date: 2003-10 Impact factor: 10.612
Authors: Hertzel C Gerstein; Michael E Miller; Robert P Byington; David C Goff; J Thomas Bigger; John B Buse; William C Cushman; Saul Genuth; Faramarz Ismail-Beigi; Richard H Grimm; Jeffrey L Probstfield; Denise G Simons-Morton; William T Friedewald Journal: N Engl J Med Date: 2008-06-06 Impact factor: 91.245
Authors: Maureen F Moen; Min Zhan; Van Doren Hsu; Lori D Walker; Lisa M Einhorn; Stephen L Seliger; Jeffrey C Fink Journal: Clin J Am Soc Nephrol Date: 2009-05-07 Impact factor: 8.237
Authors: Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh Journal: Ann Intern Med Date: 2009-05-05 Impact factor: 25.391
Authors: Denise E Bonds; Michael E Miller; Richard M Bergenstal; John B Buse; Robert P Byington; Jeff A Cutler; R James Dudl; Faramarz Ismail-Beigi; Angela R Kimel; Byron Hoogwerf; Karen R Horowitz; Peter J Savage; Elizabeth R Seaquist; Debra L Simmons; William I Sivitz; Joann M Speril-Hillen; Mary Ellen Sweeney Journal: BMJ Date: 2010-01-08
Authors: Sara Kazempour-Ardebili; Varunika L Lecamwasam; Thushara Dassanyake; Andrew H Frankel; Frederick W K Tam; Anne Dornhorst; Gary Frost; Jeremy J O Turner Journal: Diabetes Care Date: 2009-02-05 Impact factor: 17.152
Authors: Susana Hong; Lubaina Presswala; Yael T Harris; Isabela Romao; Daniel W Ross; Hugo Andrade Paz; Meng Zhang; Kenar D Jhaveri; Vipul Sakhiya; Steven Fishbane Journal: Kidney360 Date: 2020-07-09
Authors: Leila R Zelnick; Zona O Batacchi; Iram Ahmad; Ashveena Dighe; Randie R Little; Dace L Trence; Irl B Hirsch; Ian H de Boer Journal: Diabetes Care Date: 2020-08-11 Impact factor: 19.112
Authors: Elysse S Tom; Steven S Saraf; FuPeng Wang; Qinqin Zhang; Gautam Vangipuram; Christine P Limonte; Ian H de Boer; Ruikang K Wang; Kasra A Rezaei Journal: J Ophthalmol Date: 2020-11-30 Impact factor: 1.909
Authors: Laura Mayeda; Ronit Katz; Iram Ahmad; Nisha Bansal; Zona Batacchi; Irl B Hirsch; Nicole Robinson; Dace L Trence; Leila Zelnick; Ian H de Boer Journal: BMJ Open Diabetes Res Care Date: 2020-01